NASDAQ:HEPA Hepion Pharmaceuticals (HEPA) Stock Price, News & Analysis $0.07 -0.01 (-17.14%) As of 08/29/2025 03:52 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Hepion Pharmaceuticals Stock (NASDAQ:HEPA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Hepion Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.07▼$0.0850-Day Range$0.04▼$0.0852-Week Range$0.03▼$0.08Volume36,073 shsAverage Volume88,529 shsMarket Capitalization$762.71 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey. Read More Hepion Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks9th Percentile Overall ScoreHEPA MarketRank™: Hepion Pharmaceuticals scored higher than 9% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Hepion Pharmaceuticals. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Hepion Pharmaceuticals is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Hepion Pharmaceuticals is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHepion Pharmaceuticals has a P/B Ratio of 0.05. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Hepion Pharmaceuticals' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.12% of the float of Hepion Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverHepion Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Hepion Pharmaceuticals has recently decreased by 49.38%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHepion Pharmaceuticals does not currently pay a dividend.Dividend GrowthHepion Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.12% of the float of Hepion Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverHepion Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Hepion Pharmaceuticals has recently decreased by 49.38%, indicating that investor sentiment is improving significantly. News and Social Media0.6 / 5News SentimentN/A Search Interest2 people have searched for HEPA on MarketBeat in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Hepion Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.06% of the stock of Hepion Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 17.24% of the stock of Hepion Pharmaceuticals is held by institutions.Read more about Hepion Pharmaceuticals' insider trading history. Receive HEPA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hepion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HEPA Stock News HeadlinesHepion Pharmaceuticals CFO John Brancaccio resigns effective MondayJuly 1, 2025 | investing.comHepion Pharmaceuticals Successfully Completes Application to the OTCQBJune 25, 2025 | globenewswire.comOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. Then an MIT team cracked the code… dropping the cost from $63,000 to just 90 cents per gram. Now, one US-based factory is gearing up to supply the AI, aerospace, and EV industries with the one material they can’t continue to grow without. Only one company controls it, and its stock is still flying under Main Street’s radar.September 1 at 2:00 AM | True Market Insiders (Ad)HEPA Hepion Pharmaceuticals, Inc.CJune 22, 2025 | seekingalpha.comHepion Pharmaceuticals Appoints Kaouthar Lbiati As Interim CEOJune 17, 2025 | nasdaq.comHepion Pharmaceuticals reports annual meeting resultsJune 14, 2025 | investing.comHepion Pharmaceuticals, Inc.: Hepion Pharmaceuticals Announces Receipt of Delisting Notification from NasdaqMay 13, 2025 | finanznachrichten.deHepion Pharma Stock Draws Bullish Retail Bets Despite Nasdaq Delisting Notice: 'Could Get Interesting'May 12, 2025 | msn.comSee More Headlines HEPA Stock Analysis - Frequently Asked Questions How have HEPA shares performed this year? Hepion Pharmaceuticals' stock was trading at $23.5050 at the beginning of the year. Since then, HEPA shares have decreased by 99.7% and is now trading at $0.0667. How were Hepion Pharmaceuticals' earnings last quarter? Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) posted its quarterly earnings data on Sunday, November, 15th. The company reported ($690.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($510.00) by $180.00. When did Hepion Pharmaceuticals' stock split? Hepion Pharmaceuticals's stock reverse split before market open on Tuesday, March 18th 2025.The 1-50 reverse split was announced on Friday, March 14th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Monday, March 17th 2025. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. How do I buy shares of Hepion Pharmaceuticals? Shares of HEPA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Hepion Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Hepion Pharmaceuticals investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), FuelCell Energy (FCEL), NVIDIA (NVDA), Tonix Pharmaceuticals (TNXP), Advanced Micro Devices (AMD) and Meta Platforms (META). Company Calendar Last Earnings11/15/2020Today9/01/2025Next Earnings (Estimated)11/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:HEPA CIK1583771 Webwww.hepionpharma.com Phone(732) 902-4000Fax732-902-4100Employees20Year Founded2013Profitability EPS (Trailing Twelve Months)($219.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$48.93 million Net MarginsN/A Pretax MarginN/A Return on Equity-812.56% Return on Assets-207.31% Debt Debt-to-Equity RatioN/A Current Ratio1.30 Quick Ratio1.30 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.29 per share Price / Book0.05Miscellaneous Outstanding Shares11,435,000Free Float6,631,000Market Cap$762.71 thousand OptionableNo Data Beta1.52 Social Links The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:HEPA) was last updated on 9/1/2025 by MarketBeat.com Staff From Our PartnersRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredA Major Economic Change Is Happening NowLouis Navellier is one of Wall Street’s most respected money managers — overseeing more than $7 billion and ea...InvestorPlace | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A new set of 7 AI stocks are DOMINATING the market. Here’s why one financial guru says they could be the mo...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hepion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hepion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HEPA Stock Alerts